Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Operating Leases: 2019-2025

Historic Operating Leases for Theravance Biopharma (TBPH) over the last 7 years, with Sep 2025 value amounting to $33.7 million.

  • Theravance Biopharma's Operating Leases fell 17.42% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year decrease of 17.42%. This contributed to the annual value of $39.1 million for FY2024, which is 13.55% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Operating Leases is $33.7 million, which was down 5.29% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Operating Leases ranged from a high of $57.8 million in Q2 2021 and a low of $33.7 million during Q3 2025.
  • Over the past 3 years, Theravance Biopharma's median Operating Leases value was $41.1 million (recorded in 2023), while the average stood at $40.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first rose by 21.28% in 2021, then fell by 19.97% in 2023.
  • Theravance Biopharma's Operating Leases (Quarterly) stood at $52.7 million in 2021, then declined by 13.81% to $45.4 million in 2022, then decreased by 0.38% to $45.2 million in 2023, then fell by 13.55% to $39.1 million in 2024, then declined by 17.42% to $33.7 million in 2025.
  • Its Operating Leases was $33.7 million in Q3 2025, compared to $35.6 million in Q2 2025 and $37.3 million in Q1 2025.